Navigation Links
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
Date:10/9/2009

FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported continued progress in development of its lead therapeutic program for the clinic.

Under its manufacturing agreement with Wacker Biotech GmbH, a full-service contract manufacturer of biopharmaceuticals, Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having established production process parameters for PRS-050 earlier in 2009, Pieris has now met all regulatory CMC requirements to file an IND application by the end of January 2010. With toxicology studies running concurrently, PRS-050 is scheduled to commence first in man studies in the first half of 2010. Progress in the PRS-050 program demonstrates that Anticalin discovery programs can be successfully advanced from lead candidate to GMP production in around twelve months.

Commenting on these developments at Pieris, Claus Schalper, interim-CEO, said: "Sustained progress in development of PRS-050 underscores our commitment to advancing our lead Anticalin program into the clinic as quickly and efficiently as possible. This is in line with Pieris' strategy to bring Anticalins into the clinics while partnering selected project at an earlier development stage."

About Pieris AG

Pieris is a biopharmaceutical company engaged in the discovery and development of Anticalins, a novel class of targeted human proteins designed to diagnose and treat serious human disorders. Exploiting extensive know-how in protein engineering as part of a broad intellectual property portfolio, the company applies a balanced risk business model to the development of Anticalin product candidates.

About Anticalin Technology

Anticalins a
'/>"/>

SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
2. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
3. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
6. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
7. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
8. Economic Strength of Hawaii Seed Crop Industry Confirmed by Recent Reports
9. Anpath Group, Inc. Reports Progress in Japanese Market
10. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
11. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2014)... special section on single-photon detection, generation, and applications ... technologies with applications in areas as diverse as ... by providing more accurate measurement methods and new ... SPIE, the international society for optics and photonics, ... , The section appears in the August issue, ...
(Date:9/27/2014)... Texas at Dallas have created technology that could be ... sources or, more immediately, a smartphone that doesn,t die ... technology, published online in Nature Communications ... to control energy consumption inside transistors, which are at ... from the Erik Jonsson School of Engineering and Computer ...
(Date:9/26/2014)... , Sept. 26, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... the Company will hold its 2014 annual general meeting of shareholders ... Bank of China Tower, 1 Garden Road, Central, Hong ... 11, 2014 (8:00 a.m. U.S. Eastern Time on December 11, 2014). ...
(Date:9/26/2014)... Chester, NJ (PRWEB) September 26, 2014 ... of personal selling optimization technology and services for ... will present on Mobile Day at Digital Pharma ... October 21 at 10:30 a.m. , Steven Robinson, ... Director of Client Solutions, will be presenting “Test ...
Breaking Biology Technology:Single-photon detection, generation, and applications featured in Optical Engineering 2Single-photon detection, generation, and applications featured in Optical Engineering 3New UT Dallas technology may lead to prolonged power in mobile devices 2New UT Dallas technology may lead to prolonged power in mobile devices 3China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Pursuit to Present at Digital Pharma East 2
... CHARENTON-LE-PONT, France, January 10 Essilor,of America, Essilor ... in the United States with the acquisition,of Interstate ... independent,laboratories. Interstate,s two laboratories in Mansfield, Ohio and,Indianapolis, ... The,company has full-year sales of US$26 million and ...
... of,Maryland, Baltimore (UMB) BioPark today announced that Gliknik ... in the BioInnovation,Center, located in UMB BioPark,s Building ... for autoimmune diseases,and cancer, the foundation of which ... Professor and Chairman of the Department of,Otorhinolarynogology, University ...
... 9 Burrill Merchant Banking acted as,exclusive financial ... partnering of bilastine with the Menarini Group (Italy). ... bilastine rights in Europe,and other regions to Menarini ... is a new highly selective H1 antihistamine for ...
Cached Biology Technology:University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two 2Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement 2
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... have found compounds that boost liver detoxification enzymes nearly ... placethe crushed seeds left after oil extraction from an ... compounds in Camelina sativa seed, also known ... phytochemicals that work together synergistically far better than they ... supplement because its bioactive ingredients increase the liver,s ability ...
(Date:9/29/2014)... is often deemed inaccessible or esoteric. Yet in the ... in our daily lives and a decisive role in ... behind the scenes. , UC Santa Barbara,s Paul Atzberger, ... assistant professor of mechanical engineering, often works in areas ... research published in the Proceedings of the National ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes 2At the interface of math and science 2At the interface of math and science 3At the interface of math and science 4
... institutions, led by Stanford University and Brown University, have ... federal funding to learn both how the brain and ... can be done to encourage recovery from injury. ... developing the neurotechnology to ultimately enable an entirely new ...
... find answers about ovarian cancer, researchers now have something to ... been using the chicken as a model to study this ... with flaxseed decreases severity of ovarian cancer and increases survival ... of alpha-linolenic acid, one type of omega-3 fatty acid. Several ...
... normally infect rodents, but they are also infectious for ... symptoms in humans. Most importantly, these viruses have an ... any damage to healthy tissue. Therefore, scientists in the ... German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been ...
Cached Biology News:New Stanford-led program aims to produce insights into brain injury, recovery 2New Stanford-led program aims to produce insights into brain injury, recovery 3Flaxseed-fed chickens shed light on ovarian cancer 2Flaxseed-fed chickens shed light on ovarian cancer 3Viruses against cancer 2Viruses against cancer 3